Hemofilia A adquirida secundaria a un carcinoma urotelial : reporte de caso.
Acquired haemophilia A, secondary to urothelial carcinoma : a case report.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
Mostrar biografía de los autores
La hemofilia adquirida es un trastorno de difícil diagnóstico, poco prevalente, con una edad de aparición bifásica. En el 40-50% de los casos suele existir una causa subyacente. Se presenta el caso de un paciente de 79 años con equimosis atraumáticas generalizadas y hematuria de dos meses de evolución. Se documentó TTPa prolongado con TP normal, factor VIII (0,3%) y IX (53,1%); título de inhibidores contra factor VIII de 48U Bethesda. Inició manejo con complejo coagulante antiinhibidor asociado a ciclofosfamida y prednisolona. Se documentó carcinoma urotelial de bajo grado que se resecó, posterior a lo cual se logró control del sangrado, normalización de los niveles de factor VIII y desaparición del inhibidor.
Visitas del artículo 146 | Visitas PDF 196
- Franchini M, Mannucci PM. Acquired haemophilia A: a 2013 update. Thromb Haemost 2013;110(6):1114-20.
- Knoebl P, Marco P, Baudo F, Collins P, Huth-Kühne A, Nemes L, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost 2012;10(4):622-31.
- Collins PW. Therapeutic challenges in acquired factor VIII deficiency. Hematol Am Soc Hematol Educ Program 2012;2012:369-74.
- Mulliez SM, Vantilborgh A, Devreese KM. Acquired hemophilia: a case report and review of the literature. Int J Lab Hematol 2014;36(3):398-407.
- Tay L, Duncan E, Singhal D, Al-Qunfoidi R, Coghlan D, Jaksic W, et al. Twelve years of experience of acquired hemophilia A: trials and tribulations in South Australia. Semin Thromb Hemost 2009;35(8):769-77.
- Collins P, Macartney N, Davies R, Lees S, Giddings J, Majer R. A population based, unselected, consecutive cohort of patients with acquired haemophilia A. Br J Haematol 2004;124(1):86-90.
- Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M, et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood 2007;109(5):1870-7.
- Carmona E, Aznar JA, Jorquera JI, Villanueva MJ, Sánchez Cuenca JM. Detection of two different anti-factor VIII/von Willebrand factor antibodies of the IgA class in a hemophilic patient with a polyclonal factor VIII inhibitor of the IgG class. Thromb Res 1991;63(1):73-84.
- Kershaw G, Favaloro EJ. Laboratory identification of factor inhibitors: an update. Pathology 2012;44(4):293-302.
- Favaloro EJ, Verbruggen B, Miller CH. Laboratory testing for factor inhibitors. Haemoph 2014;20 Suppl 4:94-8.
- Sakurai Y, Takeda T. Acquired hemophilia A: a frequently overlooked autoimmune hemorrhagic disorder. J Immunol Res 2014;2014:320674.
- Huth-Kühne A, Baudo F, Collins P, Ingerslev J, Kessler CM, Lévesque H, et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Hematológica 2009;94(4):566-75.
- Franchini M, Gandini G, Di Paolantonio T, Mariani G. Acquired hemophilia A: a concise review. Am J Hematol 2005;80(1):55-63.
- Collins P, Baudo F, Huth-Kühne A, Ingerslev J, Kessler CM, Castellano MEM, et al. Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Res Notes 2010;3:161.
- Sborov DW, Rodgers GM. How I manage patients with acquired haemophilia A. Br J Haematol 2013;161(2):157-65.
- Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 2003;121(1):21-35.
- Zeitler H, Ulrich-Merzenich G, Hess L, Konsek E, Unkrig C, Walger P, et al. Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept. Blood 2005;105(6):2287-93.
- Nemes L, Pitlik E. New protocol for immune tolerance induction in acquired hemophilia. Haematologica 2000;85(10Suppl):64-8.
Información
